# Inhibrx (stock symbol: INBX) Logo in transparent PNG and SVG formats

## Inhibrx Logo large

### Inhibrx Logo large Download PNG (38.75 KB)

![Inhibrx Logo large Download PNG (38.75 KB)](/img/orig/INBX_BIG-32e4ccd3.png)

### Inhibrx Logo large Download SVG (4.84 KB)

![Inhibrx Logo large Download SVG (4.84 KB)](/img/orig/INBX_BIG-89bac14c.svg)

## Inhibrx Logo icon format

### Inhibrx Logo icon format Download PNG (30.96 KB)

![Inhibrx Logo icon format Download PNG (30.96 KB)](/img/orig/INBX-a1bc352b.png)

### Inhibrx Logo icon format Download SVG (1.3 KB)

![Inhibrx Logo icon format Download SVG (1.3 KB)](/img/orig/INBX-ea2a228a.svg)

## Inhibrx Logo large for dark backgrounds

### Inhibrx Logo large for dark backgrounds Download PNG (23.63 KB)

![Inhibrx Logo large for dark backgrounds Download PNG (23.63 KB)](/img/orig/INBX_BIG.D-e4fec036.png)

### Inhibrx Logo large for dark backgrounds Download SVG (4.38 KB)

![Inhibrx Logo large for dark backgrounds Download SVG (4.38 KB)](/img/orig/INBX_BIG.D-7a3862f5.svg)

## Inhibrx Logo icon format for dark backgrounds

### Inhibrx Logo icon format for dark backgrounds Download PNG (30.96 KB)

![Inhibrx Logo icon format for dark backgrounds Download PNG (30.96 KB)](/img/orig/INBX.D-f02f26eb.png)

### Inhibrx Logo icon format for dark backgrounds Download SVG (1.3 KB)

![Inhibrx Logo icon format for dark backgrounds Download SVG (1.3 KB)](/img/orig/INBX.D-23b253a8.svg)

## About Inhibrx

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

1. Website domain: inhibrx.com
2. Employees: 106
3. Marketcap: $0.91 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
